Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

USDA to Fund Research to Combat Citrus Greening Disease



The plant pathogen has spread throughout Florida’s citrus-growing areas, causing a 75 percent decline in the state’s $9 billion citrus industry.

Share this!

January 23, 2017 | by Sarah Hand, M.Sc.

The US Department of Agriculture’s (USDA) National Institute of Food and Agriculture (NIFA) has announced a $13.6 million investment in research on citrus greening disease – also known as Huanglongbing (HLB). The bacterial disease is a major threat to US citrus industry.

“The economic impact of citrus greening disease is measured in the billions,” said NIFA Director Sonny Ramaswamy. “NIFA investments in research are critical measures to help the citrus industry survive and thrive, and to encourage growers to replant with confidence.”

In 2005, the first citrus trees infected with HLB were identified in Florida. Since then, the plant pathogen has spread throughout Florida’s citrus-growing areas, causing a 75 percent decline in the state’s $9 billion citrus industry.

The Asian citrus psyllid (ACP) – an insect vector of HLB – has been found in 15 US states and territories, which have since been put under quarantine. Between 2009 and now, the USDA has invested over $400 million in citrus greening research.

In the current funding period, the USDA provided four grants to researchers at Clemson University, Regents of the University of California, Iowa State University and the USDA Agricultural Research Service (ARS). The four research centers are addressing the issue of HLB from a number of different angles.

For example, the Clemson University researchers are using the CRISPR/Cas9 genome editing technology to develop HLB-resistant citrus varieties. The Iowa State University scientists will investigate the role of soil bacteria in controlling HLB.

Past recipients of the USDA grants have developed bactericides to eliminate HLB from infected plants, and encourage future fruit production. Other previous studies have taken a preventive approach by developing citrus rootstocks with HLB immunity, using bacterial-derived virulence proteins.

Keywords: USDA, Food, Agriculture


Share this with your colleagues!

Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News

Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News

Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.